{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inspra+%28eplerenone%29&page=3", "query": { "intervention": "Inspra (eplerenone)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 52, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inspra+%28eplerenone%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inspra+%28eplerenone%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T17:00:32.465Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01807221", "title": "Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Inspra (eplerenone)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1066, "start_date": "2013-06-17", "completion_date": "2014-12-09", "has_results": true, "last_update_posted_date": "2021-07-06", "last_synced_at": "2026-10-06T17:00:32.465Z", "location_count": 10, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Macon", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807221" }, { "nct_id": "NCT02901184", "title": "Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "Spironolactone", "type": "DRUG" }, { "name": "Standard care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Uppsala University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "50 Years to 99 Years" }, "enrollment_count": 2000, "start_date": "2017-11-23", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-10-06T17:00:32.465Z", "location_count": 38, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02901184" }, { "nct_id": "NCT02871648", "title": "The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Fludrocortisone", "type": "DRUG" }, { "name": "Eplerenone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 23, "start_date": "2016-01", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-10-06T17:00:32.465Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02871648" }, { "nct_id": "NCT03888066", "title": "Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperkalemia" ], "interventions": [ { "name": "Patiromer", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vifor Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1195, "start_date": "2019-04-24", "completion_date": "2021-09-02", "has_results": true, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-10-06T17:00:32.465Z", "location_count": 133, "location_summary": "Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03888066" }, { "nct_id": "NCT04840342", "title": "MR Antagonist and LSD1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension", "Mineralocorticoid Excess" ], "interventions": [ { "name": "Eplerenone", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 300, "start_date": "2022-02-03", "completion_date": "2025-12-15", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-06T17:00:32.465Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840342" }, { "nct_id": "NCT00990223", "title": "Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Eplerenone or Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 20, "start_date": "2009-10", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2020-12-22", "last_synced_at": "2026-10-06T17:00:32.465Z", "location_count": 2, "location_summary": "Miami, Florida • South Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00990223" }, { "nct_id": "NCT00223717", "title": "Treatment of Supine Hypertension in Autonomic Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Clonidine", "type": "DRUG" }, { "name": "Nitroglycerin transdermal", "type": "DRUG" }, { "name": "Dipyridamole/ Aspirin (Aggrenox)", "type": "DRUG" }, { "name": "Desmopressin (DDAVP)", "type": "DRUG" }, { "name": "Sildenafil", "type": "DRUG" }, { "name": "Nifedipine", "type": "DRUG" }, { "name": "Hydralazine", "type": "DRUG" }, { "name": "Hydrochlorothiazide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Bosentan", "type": "DRUG" }, { "name": "Diltiazem", "type": "DRUG" }, { "name": "Eplerenone", "type": "DRUG" }, { "name": "guanfacine", "type": "DRUG" }, { "name": "L-arginine", "type": "DIETARY_SUPPLEMENT" }, { "name": "captopril", "type": "DRUG" }, { "name": "carbidopa", "type": "DRUG" }, { "name": "losartan", "type": "DRUG" }, { "name": "metoprolol tartrate", "type": "DRUG" }, { "name": "nebivolol hydrochloride", "type": "DRUG" }, { "name": "prazosin hydrochloride", "type": "DRUG" }, { "name": "tamsulosin hydrochloride", "type": "DRUG" }, { "name": "Head-up tilt.", "type": "OTHER" }, { "name": "aliskiren", "type": "DRUG" }, { "name": "Local heat stress", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 152, "start_date": "2001-01", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-10-13", "last_synced_at": "2026-10-06T17:00:32.465Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00223717" }, { "nct_id": "NCT01971593", "title": "The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Tetralogy of Fallot", "Transposition of the Great Vessels With an Arterial Switch", "Single Ventricle With a Fontan Palliation" ], "interventions": [ { "name": "Eplerenone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 26, "start_date": "2013-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2018-05-04", "last_synced_at": "2026-10-06T17:00:32.465Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01971593" }, { "nct_id": "NCT04697485", "title": "Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HF - Heart Failure", "Diabetes Mellitus" ], "interventions": [ { "name": "Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-01-08", "completion_date": "2022-03-30", "has_results": false, "last_update_posted_date": "2022-05-10", "last_synced_at": "2026-10-06T17:00:32.465Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697485" }, { "nct_id": "NCT01996449", "title": "The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Eplerenone", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" }, { "name": "Microneurography", "type": "PROCEDURE" }, { "name": "Rhythmic handgrip exercise", "type": "PROCEDURE" }, { "name": "Sustained hand grip", "type": "PROCEDURE" }, { "name": "Forearm blood flow", "type": "PROCEDURE" }, { "name": "Arm cycling exercise", "type": "PROCEDURE" }, { "name": "Cold Pressor test", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2013-07", "completion_date": "2021-04", "has_results": true, "last_update_posted_date": "2022-03-18", "last_synced_at": "2026-10-06T17:00:32.465Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01996449" } ] }